Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Nivolumab (Primary) ; Ipilimumab
- Indications Gastrointestinal stromal tumours; Liposarcoma; Osteosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 28 Mar 2018 Planned number of patients changed from 110 to 195.
- 28 Mar 2018 Planned primary completion date changed from 30 Nov 2018 to 30 Jan 2022.
- 19 Jan 2018 Status changed to suspended as per results published in the Lancet Oncology